Related Experiment Video
Updated: Jul 21, 2026

Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance
Published on: October 16, 2018
Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor)
1R&D Division, SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA.
Abstract:
The integrin alphavbeta3 is thought to play a key role in the initiation and/or progression of several human diseases, including osteoporosis, restenosis following percutaneous transluminal coronary angioplasty (PTCA), rheumatoid arthritis, cancer and ocular diseases. Antagonism of integrin alphavbeta3 is therefore expected to provide an approach for the treatment and/or prevention of these diseases. A variety of potent, small-molecule alphavbeta3 antagonists have been identified, several of which are active in disease models, thereby demonstrating the therapeutic potential of alphavbeta3 antagonism. This review will focus on recent advances in the identification of small-molecule alphavbeta3 antagonists, with an emphasis on those studies where small-molecule alphavbeta3 antagonists have been used in proof-of-concept studies in vivo.
Insights
Small molecules targeting integrin alphavbeta3 show therapeutic promise for diseases like osteoporosis and cancer. Recent research highlights potent antagonists effective in disease models, demonstrating their potential for treatment.
Area of Science:
- Integrin biology
- Pharmacology
- Disease therapeutics
Background:
- Integrin alphavbeta3 is implicated in various human diseases, including osteoporosis, restenosis, arthritis, cancer, and ocular conditions.
- Targeting integrin alphavbeta3 offers a potential therapeutic strategy for these diseases.
Purpose of the Study:
- To review recent advancements in the identification of small-molecule integrin alphavbeta3 antagonists.
- To emphasize proof-of-concept studies utilizing these antagonists in vivo for disease treatment.
Main Methods:
- Identification of potent small-molecule antagonists.
- Evaluation of antagonist activity in relevant disease models.
- In vivo proof-of-concept studies.
Main Results:
- Numerous potent small-molecule alphavbeta3 antagonists have been identified.
- Several antagonists demonstrate efficacy in preclinical disease models.
- These findings support the therapeutic potential of alphavbeta3 antagonism.
Conclusions:
- Small-molecule integrin alphavbeta3 antagonists represent a promising therapeutic avenue.
- Further development and in vivo studies are crucial for translating this potential into clinical treatments.
Related Concept Videos
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions
Some...

